OA11306A - Composition comprising 5-Ä4-Ä2-(n-2-pyridyl) amino) ethoxyÜbenzylÜbenzylÜthiazolidine-2, 4-dione - Google Patents

Composition comprising 5-Ä4-Ä2-(n-2-pyridyl) amino) ethoxyÜbenzylÜbenzylÜthiazolidine-2, 4-dione Download PDF

Info

Publication number
OA11306A
OA11306A OA9900267A OA9900267A OA11306A OA 11306 A OA11306 A OA 11306A OA 9900267 A OA9900267 A OA 9900267A OA 9900267 A OA9900267 A OA 9900267A OA 11306 A OA11306 A OA 11306A
Authority
OA
OAPI
Prior art keywords
compound
composition
pharmaceutically acceptable
acceptable form
composition according
Prior art date
Application number
OA9900267A
Other languages
English (en)
Inventor
Jai Patel
Hamish Ross
Jeffrey Roger Granett
Robin Price
Paul Nigel Wray
Original Assignee
Smithkline Beecham Corp Smithk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9712851.6A external-priority patent/GB9712851D0/en
Application filed by Smithkline Beecham Corp Smithk filed Critical Smithkline Beecham Corp Smithk
Publication of OA11306A publication Critical patent/OA11306A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
OA9900267A 1997-06-05 1999-12-02 Composition comprising 5-Ä4-Ä2-(n-2-pyridyl) amino) ethoxyÜbenzylÜbenzylÜthiazolidine-2, 4-dione OA11306A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9711683.4A GB9711683D0 (en) 1997-06-05 1997-06-05 Composition
GBGB9712851.6A GB9712851D0 (en) 1997-06-18 1997-06-18 Composition

Publications (1)

Publication Number Publication Date
OA11306A true OA11306A (en) 2003-10-22

Family

ID=26311662

Family Applications (1)

Application Number Title Priority Date Filing Date
OA9900267A OA11306A (en) 1997-06-05 1999-12-02 Composition comprising 5-Ä4-Ä2-(n-2-pyridyl) amino) ethoxyÜbenzylÜbenzylÜthiazolidine-2, 4-dione

Country Status (29)

Country Link
EP (1) EP0998284A1 (ja)
JP (1) JP2001521553A (ja)
KR (1) KR20010013410A (ja)
CN (3) CN1112926C (ja)
AP (1) AP1214A (ja)
AR (2) AR008198A1 (ja)
AU (1) AU8215098A (ja)
BG (1) BG104048A (ja)
BR (1) BR9810405A (ja)
CA (2) CA2333352A1 (ja)
CO (1) CO4940400A1 (ja)
DZ (1) DZ2510A1 (ja)
EA (1) EA002384B1 (ja)
GB (1) GB9711683D0 (ja)
HU (1) HUP0004070A3 (ja)
ID (1) ID24264A (ja)
IL (1) IL133074A0 (ja)
MX (1) MXPA99011322A (ja)
NO (2) NO995938L (ja)
NZ (2) NZ523725A (ja)
OA (1) OA11306A (ja)
PE (1) PE78899A1 (ja)
PL (1) PL337201A1 (ja)
SK (1) SK164899A3 (ja)
TR (2) TR199902963T2 (ja)
TW (1) TW570797B (ja)
UY (1) UY25032A1 (ja)
WO (1) WO1998055122A1 (ja)
ZA (2) ZA9811572B (ja)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200103061T2 (tr) 1999-04-23 2002-05-21 Smithkline Beecham P.L.C. Yeni farmasötik madde.
US20040248945A1 (en) 1999-04-23 2004-12-09 Smithkline Beecham P.L.C. Thiazolidinedione derivative and its use as antidiabetic
EP1173435B1 (en) * 1999-04-23 2003-07-30 SmithKline Beecham plc Polymorph of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt
GB0021978D0 (en) 2000-09-07 2000-10-25 Smithkline Beecham Plc Novel pharmaceutical
GB0127805D0 (en) * 2001-11-20 2002-01-09 Smithkline Beecham Plc Pharmaceutical composition
WO2003050112A1 (en) * 2001-12-13 2003-06-19 Smithkline Beecham Plc Toluenesulfonate hydrates of a thiazolidinedione derivative
GB0129876D0 (en) * 2001-12-13 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
GB0129871D0 (en) * 2001-12-13 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
GB0130509D0 (en) * 2001-12-20 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
EP2270007A1 (en) * 2006-05-09 2011-01-05 Teva Pharmaceutical Industries Ltd. 2-N-{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2-4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
US7435741B2 (en) 2006-05-09 2008-10-14 Teva Pharmaceutical Industries, Ltd. 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
WO2015008234A1 (en) * 2013-07-17 2015-01-22 Glenmark Pharmaceuticals S.A. Bicyclic heterocyclic compounds as ror gamma modulators

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE186724T1 (de) * 1987-09-04 1999-12-15 Beecham Group Plc Substituierte thiazolidindionderivate
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
WO1995021608A1 (en) * 1994-02-10 1995-08-17 Smithkline Beecham Plc Use of insulin sensitisers for treating renal diseases
SK16498A3 (en) * 1995-08-10 1999-03-12 Warner Lambert Co A method of reducing the amount of exogenous insulin administered to a patient having noninsulin-dependent diabetes mellitus
WO1997018811A1 (en) * 1995-11-17 1997-05-29 Warner-Lambert Company A method of treating myotonic dystrophy
NZ314406A (en) * 1996-03-18 2000-12-22 Sankyo Co Treatment or prophylaxis of pancreatitis with a medicament containing an insulin sensitiser including oxazoles and thiazoles
WO1998002159A1 (en) * 1996-07-12 1998-01-22 Smithkline Beecham Plc Novel treatment of leptine resistance

Also Published As

Publication number Publication date
AR015120A1 (es) 2001-04-18
AR008198A1 (es) 1999-12-29
EP0998284A1 (en) 2000-05-10
CA2292629C (en) 2004-01-06
UY25032A1 (es) 1998-11-26
BG104048A (bg) 2000-07-31
PL337201A1 (en) 2000-08-14
AU8215098A (en) 1998-12-21
NO20040738L (no) 2000-02-02
TW570797B (en) 2004-01-11
AP9901696A0 (en) 1999-12-31
EA199901116A1 (ru) 2000-06-26
CN1526391A (zh) 2004-09-08
BR9810405A (pt) 2000-08-29
ZA9811572B (en) 1999-07-22
HUP0004070A2 (hu) 2002-02-28
CN1430959A (zh) 2003-07-23
TR200002790T2 (tr) 2001-11-21
NZ523725A (en) 2004-09-24
TR199902963T2 (xx) 2000-02-21
NZ513922A (en) 2001-09-28
CN1259050A (zh) 2000-07-05
CA2333352A1 (en) 1998-12-10
DZ2510A1 (fr) 2003-01-25
NO995938L (no) 2000-02-02
NO995938D0 (no) 1999-12-03
CN1112926C (zh) 2003-07-02
WO1998055122A1 (en) 1998-12-10
KR20010013410A (ko) 2001-02-26
ZA984826B (en) 1999-08-03
SK164899A3 (en) 2000-11-07
CA2292629A1 (en) 1998-12-10
MXPA99011322A (es) 2004-12-02
JP2001521553A (ja) 2001-11-06
HUP0004070A3 (en) 2002-03-28
GB9711683D0 (en) 1997-08-06
ID24264A (id) 2000-07-13
IL133074A0 (en) 2001-03-19
PE78899A1 (es) 1999-10-22
AP1214A (en) 2003-10-08
EA002384B1 (ru) 2002-04-25
CO4940400A1 (es) 2000-07-24

Similar Documents

Publication Publication Date Title
EP1292300B1 (en) Combinations od dipeptidyl peptidase iv inhibitors and other antidiabetic agents for the treatment fo diabete mellitus
SK286029B6 (sk) Farmaceutický prostriedok a jeho použitie
CA2292629C (en) Composition comprising 5-[4-[2-(n-methyl-n-2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione
AP1287A (en) Treatment of diabetes with rosiglitazone and insulin.
US20030187030A1 (en) Composition comprising 5-[4-[2-(N-methyl-N-2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione
EP0999845B1 (en) Treatment of diabetes with thiazolidinedione and sulphonylurea
AU743269B2 (en) Treatment of diabetes with thiazolidinedione and sulphonylurea
US20040106543A1 (en) Treatment of diabetes with rosiglitazone and insulin
SK179499A3 (en) The use of insulin sensitiser and alpha-glucosidase inhibitive antihyperglycaemic agent
AU778947B2 (en) Treatment of diabetes with thiazolidinedione and metformin
AU9513401A (en) Composition comprising 5-(4-(2-(N-methyl-N-2-pyridyl) amino)ethoxy)benzyl)thiazolidine-2,4-dione
AU783539B2 (en) Treatment of diabetes with thiazolidinedione and sulphonylurea
NZ518076A (en) 5-[4-[2-(N-methyl-N-(2- pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione (BRL49653) for treating non-insulin dependent diabetes (NIDDM)
AU1552102A (en) Treatment of diabetes with rosiglitazone and insulin
MXPA99012065A (en) Treatment of diabetes with rosiglitazone and insulin
US20030073645A1 (en) Treatment of diabetes with thiazolidinedione and alpha-glucosidase inhibitor
NZ520542A (en) Treatment of diabetes with thiazolidinedione and metformin
MXPA99012098A (en) Treatment of diabetes with thiazolidinedione and alpha-glucosidase inhibitor